- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 156
TransUnion picks up Signal
Yahoo Japan has exited the customer intelligence software provider in an acquisition of undisclosed size by TransUnion following more than $78m in funding.
Aug 19, 2020DesignMedix gives up after failed trial
Portland State University spinout DesignMedix has shut down after its phase 1 trial for an antimalaria treatment caused side effects.
Aug 19, 2020JW Therapeutics to jump to public markets
The immuno-oncology company – co-founded by Juno Therapeutics, a spinout of several institutions – is reportedly seeking $250m to $300m in a Hong Kong offering.
Aug 18, 2020American Express to eat up Kabbage
American Express will acquire the SoftBank, UPS, Santander and Recruit-backed business lender's assets excluding its loan portfolio, for a reported price $350m lower than the valuation for its last round.
Aug 18, 2020JW Therapeutics to jump to public markets
WuXi AppTec and Juno Therapeutics' immuno-oncology joint venture is reportedly seeking $250m to $300m in a Hong Kong offering.
Aug 18, 2020Arctech attacks $207m initial public offering
The solar tracking technology provider is aiming for $207m in an IPO on Shanghai's Star Market having raised money in a Risen Solar-backed round last year.
Aug 18, 2020WMG tunes into IMGN Media acquisition
Dick Clark Productions, Keshet and UTA have exited the online meme and video producer in a Warner Media Group purchase reportedly sized at about $85m.
Aug 18, 2020Nano-X plans $106m IPO target
Existing investors including Foxconn, SK Telecom and iA Financial could buy up to $80m of shares in the medical imaging system developer's initial public offering.
Aug 17, 2020CureVac comes to public markets in $213m IPO
Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.
Aug 14, 2020CureVac comes to public markets in $213m IPO
GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.
Aug 14, 2020About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


